Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chance Pharma Acquires China Rights to Inhaled PAH Therapy

publication date: Mar 18, 2021

Hangzhou Chance Pharma signed a deal with Aerami Therapeutics to acquire greater China rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. Aerami is a North Carolina clinical stage biopharma that develops inhaled therapies for severe respiratory and chronic diseases. AER-901 combines a patented inhalation device with imatinib, a tyrosine kinase inhibitor specific for PDGF-Rs, c-ΚΙΤ and BCR-ABL. Chance is a clinical-stage biotech focused on inhalation therapies. Financial details were not disclosed. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.

ChinaBio® News

Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

China Healthcare Summit

November 2-3, 2023 | Shanghai

November 7-8, 2023 | Digital